Anthem Biosciences Ltd (ANTHEM) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 10039665, "name": "Anthem Bioscienc", "stock_name": "Anthem Bioscienc", "full_name": "Anthem Biosciences Ltd", "name_url": "stocks-analysis/anthem-bioscienc", "exchange": 0, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "774.45", "chg": 8.3, "chgp": "1.08%", "dir": 1, "prev_price": "766.15", "mcapval": "43,451.00 Cr", "mcap": "Mid Cap", "scripcode": 544449, "symbol": "ANTHEM", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE0CZ201020", "curr_date": "Jun 23, 03:30 PM", "curr_time": "08:27 AM", "last_traded_at": "Jun 23, 03:30 PM IST", "bse_nse_vol": "7.33 lacs", "exc_status": "Active", "traded_date": "Jun 23, 2026", "traded_date_str": "2026 06 23", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/anthem-bioscienc-10039665-0&utm_source=Spage_Header_Score", "mojoone": { "text": "Part of MojoOne Strategy", "type": "MS", "url": "https://www.marketsmojo.com/mojostocks#!#top10", "ismore": 0, "all_data": [], "is_blur": 1, "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/anthem-bioscienc-10039665-0&utm_source=Spage_Score_PartofStrategies" } }, "news": { "results": [ { "title": "Anthem Biosciences Ltd is Rated Buy by MarketsMOJO", "link": "https://www.marketsmojo.com/news/stock-recommendation/anthem-biosciences-ltd-is-rated-buy-by-marketsmojo-4051097", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AnthemBioscienc_mojoScore_4051097.png", "date": "2026-06-13 10:10:05", "description": "Anthem Biosciences Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 21 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 June 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook." }, { "title": "Anthem Biosciences Ltd is Rated Buy", "link": "https://www.marketsmojo.com/news/stock-recommendation/anthem-biosciences-ltd-is-rated-buy-4030712", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AnthemBioscienc_mojoScore_4030712.png", "date": "2026-06-02 10:10:03", "description": "Anthem Biosciences Ltd is rated Buy by MarketsMOJO, with this rating last updated on 21 May 2026. However, the analysis and financial metrics presented here reflect the company’s current position as of 02 June 2026, providing investors with the latest insights into its fundamentals, returns, and overall market stance." }, { "title": "Anthem Biosciences Ltd Technical Momentum Shifts Signal Bullish Outlook", "link": "https://www.marketsmojo.com/news/stocks-in-action/anthem-biosciences-ltd-technical-momentum-shifts-signal-bullish-outlook-4029969", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AnthemBioscienc_technicaldot_4029969.png", "date": "2026-06-02 08:11:54", "description": "Anthem Biosciences Ltd has witnessed a notable shift in its technical momentum, with key indicators signalling a transition from a mildly bullish to a bullish trend. This change, coupled with an upgrade in its Mojo Grade from Sell to Buy, reflects improving market sentiment and potential upside for investors in the Pharmaceuticals & Biotechnology sector." }, { "title": "Anthem Biosciences Ltd’s Mixed Week: -0.89% Price Change Amid Technical Shifts and Quality Upgrade", "link": "https://www.marketsmojo.com/news/stocks-in-action/anthem-biosciences-ltds-mixed-week--089-price-change-amid-technical-shifts-and-quality-upgrade-4007658", "imagepath": "", "date": "2026-05-23 09:04:42", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>18 May:</strong> Stock opens at ₹789.95, up 0.82% despite Sensex decline</p>\n <p><strong>19 May:</strong> Downgrade to Sell announced amid technical weakness and financial setbacks</p>\n <p><strong>20 May:</strong> Formation of Golden Cross signals potential bullish breakout</p>\n <p><strong>21 May:</strong> Technical momentum shifts to mildly bullish despite price decline</p>\n <p><strong>22 May:</strong> Quality grade upgraded to Excellent; rating upgraded to Buy</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</..." }, { "title": "Anthem Biosciences Ltd Upgraded to Buy on Strong Financial and Quality Improvements", "link": "https://www.marketsmojo.com/news/stock-recommendation/anthem-biosciences-ltd-upgraded-to-buy-on-strong-financial-and-quality-improvements-4004534", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AnthemBioscienc_mojoScore_4004534.png", "date": "2026-05-22 08:25:49", "description": "Anthem Biosciences Ltd has seen a significant upgrade in its investment rating from Sell to Buy as of 21 May 2026, driven by marked improvements across financial performance, quality metrics, valuation considerations, and technical indicators. This mid-cap pharmaceutical and biotechnology company’s recent quarterly results and long-term fundamentals have prompted a reassessment of its prospects, positioning it favourably against sector peers and broader market benchmarks." }, { "title": "Anthem Biosciences Ltd Upgrades Quality Grade to Excellent Amid Strong Financial Metrics", "link": "https://www.marketsmojo.com/news/stocks-in-action/anthem-biosciences-ltd-upgrades-quality-grade-to-excellent-amid-strong-financial-metrics-4004174", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AnthemBioscienc_qualitydot_4004174.png", "date": "2026-05-22 08:00:20", "description": "Anthem Biosciences Ltd has seen a significant upgrade in its quality grading from good to excellent, reflecting marked improvements in its business fundamentals. The pharmaceutical and biotechnology company’s robust sales and EBIT growth, alongside stellar returns on capital and equity, underpin this positive reassessment. Despite a slight dip in share price, the company’s financial health and operational efficiency position it favourably against peers and broader market benchmarks." }, { "title": "Has Anthem Biosciences Ltd declared dividend?", "link": "https://www.marketsmojo.com/news/stocks-in-action/has-anthem-biosciences-ltd-declared-dividend-4004046", "imagepath": "", "date": "2026-05-21 23:31:36", "description": "Anthem Biosciences Ltd has declared a 100% dividend.\n\nDividend Details:\nPercentage announced: 100%\nEx-date: 25 Jun 26\n\nDividend Yield: 0%\n\nTotal Returns by Period:\nIn the last 3 months, Anthem Biosciences Ltd achieved a price return of 13.0%, a dividend return of 0.29%, resulting in a total return of 13.29%.\n\nOver the past 6 months, the company recorded a price return of 21.11%, a dividend return of 0.32%, leading to a total return of 21.43%.\n\nFor the 1-year period, there was no price return or dividend return, resulting in a total return of 0.0%.\n\nIn the 2-year period, the company saw no price return or dividend return, culminating in a total return of 0.0%.\n\nOver the last 3 years, there were no price or dividend returns, resulting in a total return of 0.0%.\n\nIn the 4-year period, there was no price return or dividend return, leading to a total return of 0.0%.\n\nFinally, in the 5-year period, there were no ..." }, { "title": "Are Anthem Biosciences Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-anthem-biosciences-ltd-latest-results-good-or-bad-4003660", "imagepath": "", "date": "2026-05-21 19:31:16", "description": "Anthem Biosciences Ltd reported its Q4 FY26 results, showcasing significant operational achievements. The company recorded a net profit of ₹189.76 crores, reflecting a notable increase compared to the previous quarter, where it was ₹92.82 crores. This performance indicates a strong recovery from the subdued results of the prior quarter. Revenue for the same quarter reached ₹610.94 crores, marking a substantial rise from ₹423.15 crores in Q3 FY26. This quarter also saw the highest sales in the company's history, with a sequential growth of 44.38% and a year-on-year growth of 26.44%.\n\nThe operating margin improved to 43.74%, up from 37.15% in the previous quarter, indicating enhanced operational efficiency. Additionally, the return on equity (ROE) stood at 24.12%, reflecting strong capital efficiency. The company’s performance was bolstered by effective cost management and a favorable project mix, leading to ..." }, { "title": "Anthem Biosciences Ltd Technical Momentum Shifts to Mildly Bullish Amid Mixed Market Returns", "link": "https://www.marketsmojo.com/news/stocks-in-action/anthem-biosciences-ltd-technical-momentum-shifts-to-mildly-bullish-amid-mixed-market-returns-4002245", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AnthemBioscienc_technicaldot_4002245.png", "date": "2026-05-21 08:04:48", "description": "Anthem Biosciences Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish to a mildly bullish trend. Despite a recent day decline of 0.87%, the stock’s technical indicators reveal a complex picture of emerging strength tempered by caution, as investors weigh the implications of mixed signals from key momentum and volume metrics." } ], "total": 50, "sid": "10039665", "stock_news_url": "https://www.marketsmojo.com/news/anthem-biosciences-10039665" }, "announcements": [ { "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011", "datetime": "19-Jun-2026", "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Aruna Ganesh", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation", "datetime": "05-Jun-2026", "details": "Schedule of Institutional Call to be held on June 10 2026", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation", "datetime": "22-May-2026", "details": "Investors/Analyst Call Intimation to be schedule from June 02 2026 till June 05 2026.", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Anthem Biosciences Ltd has declared <strong>100%</strong> dividend, ex-date: 25 Jun 26", "dt": "2026-06-25", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

18 May: Stock opens at ₹789.95, up 0.82% despite Sensex decline

19 May: Downgrade to Sell announced amid technical weakness and financial setbacks

20 May: Formation of Golden Cross signals potential bullish breakout

21 May: Technical momentum shifts to mildly bullish despite price decline

22 May: Quality grade upgraded to Excellent; rating upgraded to Buy

Week OpenRead full news article

Anthem Biosciences Ltd Upgraded to Buy on Strong Financial and Quality Improvements

2026-05-22 08:25:49

Anthem Biosciences Ltd has seen a significant upgrade in its investment rating from Sell to Buy as of 21 May 2026, driven by marked improvements across financial performance, quality metrics, valuation considerations, and technical indicators. This mid-cap pharmaceutical and biotechnology company’s recent quarterly results and long-term fundamentals have prompted a reassessment of its prospects, positioning it favourably against sector peers and broader market benchmarks.

Read full news article

Anthem Biosciences Ltd Upgrades Quality Grade to Excellent Amid Strong Financial Metrics

2026-05-22 08:00:20

Anthem Biosciences Ltd has seen a significant upgrade in its quality grading from good to excellent, reflecting marked improvements in its business fundamentals. The pharmaceutical and biotechnology company’s robust sales and EBIT growth, alongside stellar returns on capital and equity, underpin this positive reassessment. Despite a slight dip in share price, the company’s financial health and operational efficiency position it favourably against peers and broader market benchmarks.

Read full news article

Has Anthem Biosciences Ltd declared dividend?

2026-05-21 23:31:36

Anthem Biosciences Ltd has declared a 100% dividend. Dividend Details: Percentage announced: 100% Ex-date: 25 Jun 26 Dividend Yield: 0% Total Returns by Period: In the last 3 months, Anthem Biosciences Ltd achieved a price return of 13.0%, a dividend return of 0.29%, resulting in a total return of 13.29%. Over the past 6 months, the company recorded a price return of 21.11%, a dividend return of 0.32%, leading to a total return of 21.43%. For the 1-year period, there was no price return or dividend return, resulting in a total return of 0.0%. In the 2-year period, the company saw no price return or dividend return, culminating in a total return of 0.0%. Over the last 3 years, there were no price or dividend returns, resulting in a total return of 0.0%. In the 4-year period, there was no price return or dividend return, leading to a total return of 0.0%. Finally, in the 5-year period, there were no ...

Read full news article

Are Anthem Biosciences Ltd latest results good or bad?

2026-05-21 19:31:16

Anthem Biosciences Ltd reported its Q4 FY26 results, showcasing significant operational achievements. The company recorded a net profit of ₹189.76 crores, reflecting a notable increase compared to the previous quarter, where it was ₹92.82 crores. This performance indicates a strong recovery from the subdued results of the prior quarter. Revenue for the same quarter reached ₹610.94 crores, marking a substantial rise from ₹423.15 crores in Q3 FY26. This quarter also saw the highest sales in the company's history, with a sequential growth of 44.38% and a year-on-year growth of 26.44%. The operating margin improved to 43.74%, up from 37.15% in the previous quarter, indicating enhanced operational efficiency. Additionally, the return on equity (ROE) stood at 24.12%, reflecting strong capital efficiency. The company’s performance was bolstered by effective cost management and a favorable project mix, leading to ...

Read full news article

Anthem Biosciences Ltd Technical Momentum Shifts to Mildly Bullish Amid Mixed Market Returns

2026-05-21 08:04:48

Anthem Biosciences Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish to a mildly bullish trend. Despite a recent day decline of 0.87%, the stock’s technical indicators reveal a complex picture of emerging strength tempered by caution, as investors weigh the implications of mixed signals from key momentum and volume metrics.

Read full news article